[go: up one dir, main page]

WO2010136900A3 - Methods of using krill oil to treat risk factors for metabolic disorders and obesity - Google Patents

Methods of using krill oil to treat risk factors for metabolic disorders and obesity Download PDF

Info

Publication number
WO2010136900A3
WO2010136900A3 PCT/IB2010/001478 IB2010001478W WO2010136900A3 WO 2010136900 A3 WO2010136900 A3 WO 2010136900A3 IB 2010001478 W IB2010001478 W IB 2010001478W WO 2010136900 A3 WO2010136900 A3 WO 2010136900A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
krill oil
risk factors
obesity
metabolic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/001478
Other languages
French (fr)
Other versions
WO2010136900A2 (en
Inventor
Inge Bruheim
Snorre Tilseth
Jeffrey Cohn
Mikko Griinari
Sebastiano Banni
Daniele Mancinelli
Nils Hoem
Hogne Vik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aker Biomarine ASA
Original Assignee
Aker Biomarine ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aker Biomarine ASA filed Critical Aker Biomarine ASA
Priority to CA2763647A priority Critical patent/CA2763647A1/en
Priority to EP10740706A priority patent/EP2435055A2/en
Publication of WO2010136900A2 publication Critical patent/WO2010136900A2/en
Publication of WO2010136900A3 publication Critical patent/WO2010136900A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Insects & Arthropods (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondrial respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.
PCT/IB2010/001478 2009-05-28 2010-05-28 Methods of using krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders Ceased WO2010136900A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2763647A CA2763647A1 (en) 2009-05-28 2010-05-28 Methods of using krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders
EP10740706A EP2435055A2 (en) 2009-05-28 2010-05-28 Methods of using krill oil to treat risk factors for metabolic disorders and obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18174309P 2009-05-28 2009-05-28
US61/181,743 2009-05-28

Publications (2)

Publication Number Publication Date
WO2010136900A2 WO2010136900A2 (en) 2010-12-02
WO2010136900A3 true WO2010136900A3 (en) 2011-06-16

Family

ID=43034639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/001478 Ceased WO2010136900A2 (en) 2009-05-28 2010-05-28 Methods of using krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders

Country Status (3)

Country Link
EP (1) EP2435055A2 (en)
CA (1) CA2763647A1 (en)
WO (1) WO2010136900A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609157B2 (en) 2009-10-30 2013-12-17 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
CN103096904B (en) * 2010-09-01 2016-03-09 日本水产株式会社 Alcoholic injury alleviant
CN103327982A (en) * 2011-02-01 2013-09-25 日本水产株式会社 Sexual function improving agent
WO2012103685A1 (en) * 2011-02-01 2012-08-09 Nippon Suisan Kaisha, Ltd. Sexual function improving agent
WO2013033618A1 (en) 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content
WO2013160914A1 (en) * 2012-04-25 2013-10-31 Ezhil Arasan Ramanan Novel synergistic composition comprising of a carotenoid, serm and an amino acid derivative thereof
FR3015860B1 (en) * 2013-12-30 2019-08-16 Pronokal Health Group, Sociedad Limitada DIET FOOD COMPOSITION FOR REDUCING LOW AND LONG-TERM LOW-GRADE INFLAMMATION COMPRISING DOCOSAHEXAENOIC ACID
AU2015329663A1 (en) * 2014-10-10 2017-04-27 Aker Biomarine Antarctic As Marine lecithin preparations with enhanced oxidation resistance
JP6814148B2 (en) 2015-03-31 2021-01-13 フレゼニウス カービ ドイチュラント ゲーエムベーハー Emulsion for parenteral administration
US10328105B2 (en) 2015-05-27 2019-06-25 Rimfrost Technologies As Flowable concentrated phospholipid krill oil composition
CN107987948A (en) * 2017-06-25 2018-05-04 青岛康境海洋生物科技有限公司 A kind of krill oil formulation for adjusting blood fat
WO2020055913A1 (en) * 2018-09-10 2020-03-19 Cardax, Inc. Methods of reducing- c-reactive protein and/or treating cardiovascular disease
WO2021138742A1 (en) * 2020-01-10 2021-07-15 Acasti Pharma Inc. Composition that promote pro-resolving mediators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102394A2 (en) * 2001-06-18 2002-12-27 Neptune Technologies & Bioressources Inc. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
US20060078625A1 (en) * 2004-10-08 2006-04-13 Susie Rockway Compositions including krill extracts and conjugated linoleic acid and methods of using same
WO2007080515A1 (en) * 2006-01-13 2007-07-19 Aker Biomarine Asa Thrombosis preventing krill extract
US20080166419A1 (en) * 2007-01-04 2008-07-10 Sones Scott F Krill oil compositions
WO2008117062A1 (en) * 2007-03-28 2008-10-02 Aker Biomarine Asa Bioeffective krill oil compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2909508B2 (en) 1989-02-14 1999-06-23 マルハ株式会社 Krill phospholipid fractionation method
CA2251265A1 (en) 1998-10-21 2000-04-21 Universite De Sherbrooke Process for lipid extraction of aquatic animal tissues producing a dehydrated residue
EP1417211B1 (en) 2001-07-27 2007-05-30 Neptune Technologies & Bioressources Inc. Natural phospholipids of marine origin containing flavonoids and polyunsaturated phospholipids and their uses
KR20060008155A (en) 2004-07-23 2006-01-26 최희성 Glucosamine and Krill Oil Combination to Prevent Degenerative Arthritis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102394A2 (en) * 2001-06-18 2002-12-27 Neptune Technologies & Bioressources Inc. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
US20060078625A1 (en) * 2004-10-08 2006-04-13 Susie Rockway Compositions including krill extracts and conjugated linoleic acid and methods of using same
WO2007080515A1 (en) * 2006-01-13 2007-07-19 Aker Biomarine Asa Thrombosis preventing krill extract
US20080166419A1 (en) * 2007-01-04 2008-07-10 Sones Scott F Krill oil compositions
WO2008117062A1 (en) * 2007-03-28 2008-10-02 Aker Biomarine Asa Bioeffective krill oil compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUNEA R ET AL: "Evaluation of the effects of neptune krill oil on the clinical course of hyperlipidemia", ALTERNATIVE MEDICINE REVIEW, THORNE RESEARCH INC., SANDPOINT, US, vol. 9, no. 4, 1 January 2004 (2004-01-01), pages 420 - 428, XP002430956, ISSN: 1089-5159 *

Also Published As

Publication number Publication date
WO2010136900A2 (en) 2010-12-02
EP2435055A2 (en) 2012-04-04
CA2763647A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
WO2010136900A3 (en) Methods of using krill oil to treat risk factors for metabolic disorders and obesity
MY158504A (en) Fatty acid niacin conjugates and their uses
WO2008042688A3 (en) Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
WO2013153071A3 (en) A nutritional composition
WO2012119078A3 (en) COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
GB2459809A (en) Fatty acid formulations and methods of use thereof
WO2011060945A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
WO2008129358A8 (en) Oil producing microbes and methods of modification thereof
WO2009126688A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2009150023A3 (en) Method for producing sphingolipids by enzymatic n-acylation of lysosphingolipids using a lipase and a fatty acid glycerol ester
WO2007149865A3 (en) Methods and compositions related to inhibition of ceramide synthesis
WO2006108582A3 (en) Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis
MX2010003703A (en) Composition comprising polyunsaturated fatty acids and activated charcoal.
WO2009048249A3 (en) Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same
WO2011060944A3 (en) Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
MX2009004339A (en) Fatty acid alcohols.
MX2010003843A (en) Orodispersible composition comprising polyunsaturated fatty acids without bad odour or taste.
IL198286A (en) Use of an indazolemethoxyalkanoic acid for preparing pharmaceutical compositions for reducing triglyceride, cholesterol and glucose levels
WO2014089511A3 (en) Administering compositions comprising docosapentaenoic acid
WO2010028336A3 (en) Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
WO2006109194A3 (en) Chromium-fatty acid compounds and methods of making and using thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10740706

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2763647

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010740706

Country of ref document: EP